Controversy heats up over amlodipine issue

A controversy is brewing over the approval of Pfizer's amlodipine generic versions after some media's report on the Korea Food and Drug Administration's intention to permit the omission of clinical trials on latecomer's me-too products.

In response, the KFDA clarified recently that it did not intend to side with latecomers, such as Daewoong and Yuhan Corp. on their me-too products of amodipi...